Liver function in patients with pulmonary tuberculosis (PT) before and during the initial phase of antituberculosis treatment (ATT)

S. Golubovic, D. Zivkovic, G. Pejovic, M. Radovic, D. Dacic, I. Djordjevic (Nis, Yugoslavia)

Source: Annual Congress 2002 - Clinical events related to tuberculosis
Session: Clinical events related to tuberculosis
Session type: Thematic Poster Session
Number: 2255
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Golubovic, D. Zivkovic, G. Pejovic, M. Radovic, D. Dacic, I. Djordjevic (Nis, Yugoslavia). Liver function in patients with pulmonary tuberculosis (PT) before and during the initial phase of antituberculosis treatment (ATT). Eur Respir J 2002; 20: Suppl. 38, 2255

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Primary resistance (PR) of mycobacterium tuberculosis (MBT) to antimicrobial drugs (AMBD) in patients (P) with destructive pulmonary tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 655s
Year: 2004

The efficacy of treatment with surfactant-BL (S-BL) in patients with destructive pulmonary tuberculosis
Source: Annual Congress 2007 - Research perspectives: diagnosis and treatment of tuberculosis
Year: 2007


Treatment patients with pulmonary tuberculosis (PT) and accompanying pathologies by DOTS strategy
Source: Eur Respir J 2005; 26: Suppl. 49, 192s
Year: 2005

Recurrence after successful treatment of pulmonary tuberculosis (TB) with multidrug-resistance (MDR)
Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis
Year: 2008


Pitfalls in the registration and delay in the treatment of patients with culture positive pulmonary tuberculosis (CPPTB)
Source: Annual Congress 2007 - New methods to diagnose tuberculosis infection and disease and problems in tuberculosis care
Year: 2007


Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF)
Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis
Year: 2020


Accompanying therapy of patients with extensive drug-resistant (xdr) lung tuberculosis
Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Year: 2018


Combined collapse therapy in the treatment of cavitary pulmonary tuberculosis (CPTB)
Source: International Congress 2015 – Management of TB: a patient focus
Year: 2015

Pulmonary tuberculosis (PT) in patients taking the TNF-a inhibitor inflixinab (INF)
Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts
Year: 2011


Use of surfactant-BL (S-BL) in complex treatment of pulmonary TB patients
Source: Eur Respir J 2003; 22: Suppl. 45, 521s
Year: 2003

Primary multidrug resistance (PMDR) of mycobacterium tuberculosis (MBT) to antimycobacterial drugs (AMBTD) in the patients with destructive TB.
Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis
Year: 2008

Individualized treatment regimens with second line anti-TB drugs (SLD) compared to first line anti-TB drug (FLD) only in new pulmonary TB patients, culture confirmed with full sensibility at drug sensibility test (DST)
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011

Surgical treatment of destructive pulmonary tuberculosis (TB) with multi-drug resistance (MDR)
Source: Eur Respir J 2004; 24: Suppl. 48, 723s
Year: 2004

Long term plasma rifampicin (R) concentrations in AIDS patients with tuberculosis (TB) under HAART therapy
Source: Eur Respir J 2003; 22: Suppl. 45, 40s
Year: 2003

The efficiency of the treatment of the patients with culture-positive pulmonary tuberculosis (CPPTB) in Gdannsk, Poland in 1995 and 2000
Source: Annual Congress 2005 - Epidemiology and control of tuberculosis and LTBI
Year: 2005


Disease severity for enrollment criteria of patients with idiopathic pulmonary fibrosis (IPF) in clinical trial: evaluation of time to first episode of acute exacerbation (TTA)
Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis
Year: 2009

The use of phon resonant therapy (PRT) in treatment of patients with pulmonary tuberculosis, combined with infections, caused by chlamydia (C) and mycoplasma (M)
Source: Eur Respir J 2004; 24: Suppl. 48, 52s
Year: 2004

Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis
Source: Eur Respir J 2001; 18: Suppl. 33, 339s
Year: 2001

Bio-Chip (BCh) technology for diagnostics of multidrug resistance (DR) of mycobacterium tuberculosis (MBT) from patients with disseminated tuberculosis (DT)
Source: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis
Year: 2008


Almost half the patients treated for pulmonary tuberculosis (TB) show evidence of obstructive airways disease (OAD)
Source: Annual Congress 2007 - Epidemiological and clinical aspects of tuberculosis control
Year: 2007